Becton Dickinson Set to Outperform Earnings Estimates: Is It a Buy?
January 31, 2023
Trending News 🌥️
Becton ($NYSE:BDX) Dickinson (BDX) is a global medical technology company that manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products. BDX is known for its innovative products and services that are used by healthcare providers, researchers, and patients around the world. Recently, the company has been setting itself up to outperform its earnings estimates in the upcoming quarter. As a result, many investors are wondering if it is a good buy. The answer to this question depends on several factors.
First, investors should consider the company’s financial performance. BDX has a strong balance sheet with healthy cash reserves and low debt levels. Furthermore, its earnings have consistently been above expectations in recent quarters. This indicates that the company is well-positioned to deliver positive results in the upcoming quarter. Second, investors should consider the company’s competitive position. BDX has a strong presence in the medical device market, which is expected to grow significantly in the coming years. The company also has a broad portfolio of products and services that it can leverage for growth. Finally, the company has been investing heavily in research and development, which should help it stay ahead of the competition and remain profitable in the long run. In conclusion, Becton Dickinson appears to have the right ingredients to outperform its earnings estimates in the upcoming quarter. The company has a strong financial position, a competitive position in the medical device market, and has been investing significantly in R&D. As a result, investors may want to consider buying BDX ahead of its expected earnings beat.
Price History
On Friday, BECTON stock opened at $249.3 and closed at $251.8, up by 1.1% from prior closing price of 249.1. This increase was likely a result of investors’ anticipation of the upcoming earnings report. Analysts are expecting Becton Dickinson to beat their estimates for the quarter. The company’s fourth quarter results are estimated to show an improvement from the third quarter, and investors are optimistic about the company’s performance. Furthermore, the company’s long term prospects are looking positive due to its growing presence in emerging markets, as well as its focus on innovation and research and development. With the stock price already up over 1% from its previous close, now could be an attractive time for investors to consider taking a position in the stock.
However, it is important to keep in mind that there is always a risk associated with investing in any company, and investors should do their own research before deciding to buy or sell any stock. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Becton. More…
| Total Revenues | Net Income | Net Margin |
| 18.87k | 1.69k | 11.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Becton. More…
| Operations | Investing | Financing |
| 2.61k | -1.88k | -3.31k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Becton. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.2k | 27.7k | 89.39 |
Key Ratios Snapshot
Some of the financial key ratios for Becton are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 3.0% | 3.4% | 13.4% |
| FCF Margin | ROE | ROA |
| 7.8% | 5.3% | 2.6% |
VI Analysis
VI App is a great tool for analyzing the fundamentals of BECTON, which gives you an insight into its long-term potential. The app’s VI Risk Rating has classified BECTON as a medium risk investment taking into account its financial and business aspects. The app has detected two risk warnings in the income sheet and balance sheet. These warnings could be indicative of potential issues that should be further investigated before investing in BECTON. VI App helps investors make informed decisions by providing them with up-to-date and reliable data. It is an invaluable resource for investors who are looking to analyze the company’s fundamentals before investing their hard-earned money. The app offers a variety of analytical tools and features, such as the ability to compare BECTON to other companies in its industry, as well as generate graphs and charts that visualize relevant financial data. It also provides users with an overview of the company’s key performance indicators, such as growth rate, profit margins, and debt-to-equity ratio. In addition, VI App enables users to assess the company’s future prospects by assessing their current financials and making informed predictions based on the data. The app also provides insights into how BECTON’s performance stacks up against its peers. Overall, VI App makes it easy for investors to assess BECTON’s long-term potential and make informed decisions about their investments. To take advantage of the app’s features, register with us today and gain access to all the data you need to make informed decisions about your investments. More…
VI Peers
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.
– Penumbra Inc ($NYSE:PEN)
Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.
Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.
The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.
– Teleflex Inc ($NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.
– SheerVision Inc ($OTCPK:SVSO)
SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.
Summary
Investing in Becton Dickinson stock is a potentially wise decision. Analysts are projecting that the company will outperform earnings estimates this quarter. Its products are used by healthcare professionals and consumers across the world, and it has a strong presence in the healthcare industry. Investors should consider the company’s competitive advantages, financial stability, and future growth prospects before making a purchase decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
